Revamping best-selling drugs to combat patent cliff has limits [Yahoo! Finance]
Regeneron Pharmaceuticals, Inc. (REGN)
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.regeneron.com
Company Research
Source: Yahoo! Finance
Patent expiry is a phenomenon that haunts every pharmaceutical company, with the loss of market exclusivity often causing a dramatic dip in a company's profits. This can be particularly challenging for companies whose drug is one of their best-sellers – having the potential to wipe billions from revenue figures. With a particularly large wave of drug patent expiries set to hit the industry in the coming years, the spotlight on the state of biopharma pipelines has intensified. To combat the challenges associated with the patent cliff, pharma companies are increasingly licensing new and promising assets, with many looking to China for this as the country enhances its output of potential first- and best-in-class pipeline assets. However, companies are also revamping their best-selling medicines – improving aspects like durability, route of administration, potency, tolerability, and more, to extend their market potential in the face of biosimilar competition. This trend is strong
Show less
Read more
Impact Snapshot
Event Time:
REGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
REGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
REGN alerts
High impacting Regeneron Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
REGN
News
- 3 Cash-Heavy Stocks We Approach with Caution [Yahoo! Finance]Yahoo! Finance
- Morgan Stanley Sees Policy Risks Receding for Regeneron (REGN) [Yahoo! Finance]Yahoo! Finance
- Vyriad Secures Final $25M Series B Tranche to Advance In Vivo CAR T Candidate into Clinic [Yahoo! Finance]Yahoo! Finance
- Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial AsthmaGlobeNewswire
- Regeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
REGN
Earnings
- 10/28/25 - Beat
REGN
Sec Filings
- 12/11/25 - Form 4
- 12/11/25 - Form 4
- 12/11/25 - Form 4
- REGN's page on the SEC website